Ad
Search
Generic filters
Filter by content type
Taxonomy terms

SNDX – Syndax Pharmaceuticals Inc

🔒

Subscribe for full access

Unlock Industry-grade Shariah Compliance for US, UK, Canada, Germany, GCC, Europe and India. See results from 5 major Shariah standards: AAOIFI, S&P, DJIM, FTSE and MSCI.

We provide unparalleled value and service.

Get started from just $1/month

Ad

Recommendation Rating

1.71

1

2

3

4

5

1 = STRONG BUY | 2 = BUY | 3 = HOLD | 4 = UNDERPERFORM | 5 = SELL

Analysts’ Price Targets

Mean 31.14

Low: 26

High: 35

Total Analysts: 6

Company Profile

Syndax Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company that is focused on developing a pipeline of cancer therapies. The Company’s lead product candidates include SNDX-5613 and SNDX-6352 (axatilimab). The Company is focused on developing SNDX-5613, targeting the binding interaction of menin with the mixed lineage leukemia 1 (MLL1), protein for the treatment of MLL-rearranged (MLLr), acute leukemias and nucleophosmin 1 (NPM1), mutant acute myeloid leukemia (AML), as well as axatilimab, a monoclonal antibody that blocks the colony stimulating factor 1 (CSF-1) receptor. The Company’s products candidate also includes entinostat, once-weekly, oral, small molecule and Class I histone deacetylases (HDAC) inhibitor that being evaluated in the Phase III E2112 registrational clinical trial in combination with exemestane for hormone receptor positive, human epidermal growth factor receptor 2 negative and breast cancer.

We do our best to screen stocks as accurately as possible. Please let us know in the comments if you spot an error or find something questionable. Jazaak Allahu khairan

Ad

Responses